<DOC>
	<DOCNO>NCT01310881</DOCNO>
	<brief_summary>This subject single blind , randomize , placebo-controlled , single dose , first-time-in-human study three ascend cohort .</brief_summary>
	<brief_title>Single-Dose Pharmacokinetics ( PK ) Study Novel Neurogenic Compound NSI-189</brief_title>
	<detailed_description>Each subject undergo Screening ( Day -28 Day -2 ) . Subjects return clinical site Day -1 , admit unit , eligibility reconfirm . Eligible subject receive single dose investigational medicinal product ( IMP , NSI-189 Phosphate Placebo ) Day 1 follow safety PK discharge Day 3 . Subjects experience significant AEs consider possibly relate study drug keep unit additional day ( longer ) event resolve consider medically safe subject discharge . Subjects telephone Follow-up Day 4 return unit Day 7 ( ± 1 ) End-of-study . Participation individual subject may last 36 day time Screening End-of-study .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<criteria>A subject must meet following criterion : 1 . Subject ability understand purpose risk study provide sign date informed consent . 2 . Males females 18 55 year age , inclusive , time informed consent . 3 . The following applies female subject : • Nonchildbearing potential ( surgically sterile [ hysterectomy bilateral tubal ligation ] postmenopausal ≥ 1 year follicle stimulate hormone &gt; 40 U/L ) . 4 . The following applies male subject : • Male subject female partner childbearing potential require use effective method birth control practice abstinence study 3 month follow discontinuation IMP . 5 . Nonsmokers ( nicotine use ) determine history ( nicotine use past year ) negative urine cotinine test screen Day 1 . 6 . BMI ≥ 19.5 ≤30.0 kg/m2 , screen . Bodyweight must &gt; 50 kg . 7 . Healthy , determine prestudy medical evaluation investigator discretion ( medical history , physical examination , vital sign , ECG , clinical laboratory evaluation ) . 1 . Clinically significant history evidence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , neurological , immunological , dermatological psychiatric disorder ( ) , major disease determine Investigator designee . 2 . History seizure include febrile seizure , loss consciousness , clinically significant find neurologic examination . 3 . Clinically significant abnormal clinical chemistry value , determine Investigator . 4 . Clinically significant ( determined Investigator ) 12lead ECG abnormality , include correct QT interval use Bazett 's correction method &gt; 450 msec male &gt; 470 msec female . 5 . History severe allergic anaphylactic reaction . 6 . Subjects plan undergo elective procedures/surgeries time study followup visit . 7 . A positive screening test human immunodeficiency virus ( HIV ) , hepatitis C virus antibody ( HCVAb ) , hepatitis B core antibody ( HBcAb ) , hepatitis B surface antigen ( HBsAg ) . 8 . Serious infection ( e.g . pneumonia , septicemia ) determine Investigator within 3 month prior Day 1 . 9 . Fever bacterial , viral infection ( include upper respiratory tract infection ) within 2 week prior Day 1 . 10 . Treatment prescribed medication within 28 day prior Day 1 . 11 . Treatment overthecounter product ( OTC ) , include herbal and/or alternative health preparation procedure within 14 day prior Day 1 . Note : Intermittent treatment acetaminophen [ ≤1000 mg/day ] and/or ibuprofen [ ≤400 mg/day ] permit . 12 . Current enrollment drug , biologic , device , clinical study , treatment investigational product approve therapy investigational use within 30 day ( 5 halflives , whichever long ) prior Day 1 . 13 . Any live attenuate immunization/vaccination within 1 month prior study drug administration plan occur study period . 14 . Donation blood ( &gt; 500 mL ) blood product within 1 month prior screen . 15 . History alcohol substance abuse ( cocaine , amphetamine , barbiturate , opiate , benzodiazepine , cannabinoids , etc . ) ( determine Investigator ) . 16 . Vigorous exercise ( determined Investigator ) within 48 hour prior study drug administration . 17 . Inability comply study requirement . 18 . Any disorder would interfere absorption , distribution , metabolism , excretion drug . 19 . Any concurrent disease condition , opinion Investigator , would make subject unsuitable participation clinical study . 20 . Subject unwilling avoid consumption coffee caffeine contain beverage within 48 hour prior Day 1 discharge clinical site . 21 . Use investigational product within 30 day prior Day 1 . 22 . Subject unable understand protocol requirement , instruction studyrelated restriction , nature , scope possible consequence clinical study . 23 . Subject unlikely comply protocol requirement , instruction studyrelated restriction . 24 . Subject previously enrol clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Neurogenesis</keyword>
	<keyword>hippocampal stem cell</keyword>
	<keyword>depression</keyword>
	<keyword>stroke</keyword>
</DOC>